UK and Japan strengthen science and technology ties

The UK and Japan have introduced a serious bundle of science and technology collaborations, strengthening ties between 2 of the world’s main innovation hubs.  

The bulletins being detailed at this time (Tuesday 3 February) have been confirmed throughout the Prime Minister’s go to to Japan on Saturday, the place he dedicated to deepening the science and tech ties between our 2 international locations. 

These bulletins span life sciences, quantum and connectivity tech. The tasks are geared in direction of creating cures for uncommon genetic illnesses and bringing ultra-fast cell protection to each a part of the UK.   

Leaders additionally agreed to carry the Japan-UK Joint Committee on Cooperation in Science and Technology for the primary time in 3 years, and to set up a brand new area session. 

In a lift for UK life sciences manufacturing, Orchard Therapeutics, the UK subsidiary of Japanese firm Kyowa Kirin, is about to take a position round £11 million within the UK. Subject to closing settlement of phrases and circumstances of the UK authorities’s Life Sciences Innovative Manufacturing Fund, the funding will go in direction of the invention of recent medication which may deal with and beat illnesses – remodeling outcomes for sufferers. 

This bundle of reports provides to the £33 billion in bilateral commerce between the UK and Japan. From collaboration on breakthrough applied sciences, to cooperation in high-growth financial sectors like area and cyber, via to the alternatives supplied via each international locations’ affiliation to Horizon Europe, there are huge avenues by which the UK and Japan may go even additional unlock the promise of science and technology to develop our economies and enhance lives.

Science Minister Lord Vallance mentioned: 

These bulletins, masking life sciences, quantum and extra, highlight a few of the key science-driven industries through which the UK and Japan are working collectively. The prizes on supply embody new therapies for illnesses that have been beforehand thought-about untreatable, and essential infrastructure for the digital age. 

It’s essential that British and Japanese scientific and business partnerships proceed to flourish, so we are able to develop our economies, create jobs, and give hope to sufferers battling a few of the cruellest illnesses.

The funding by Kyowa Kirin into Orchard Therapeutics paves the way in which for gene therapies for devastating diseases to be researched and developed within the UK – supporting excessive‑expert jobs and serving to guarantee sufferers can entry probably the most modern therapies, with additional potential funding in R&D to observe.  

It builds on the success of Libmeldy (atidarsagene autotemcel), a revolutionary remedy developed by the corporate to deal with youngsters with metachromatic leukodystrophy. This uncommon and deadly genetic illness causes extreme harm to the affected little one’s nervous system and organs, however Orchard’s gene remedy, which is obtainable on the NHS, saves lives by inserting working copies of a defective gene in a affected person’s personal blood stem cells. 

And, in one other step forwards in deepening UK–Japan collaboration in life sciences, modern British genomics agency, Oxford Nanopore Technologies, will enter into a multi-year strategic partnership with Japanese genetic testing supplier Genesis Healthcare (A.D.A.M Innovations).  Following a UK government-led engineering biology commerce mission to Japan in October 2025, the two firms are agreeing Heads of Terms to provoke a nationwide pilot targeted on remodeling screening for uncommon illnesses. 

The UK and Japan are additionally launching 3 new joint quantum technology analysis tasks, bringing collectively main researchers from each international locations to deal with challenges ranging from drug discovery and safe communications, to navigation in environments the place GPS is unavailable. 

The tasks – ranging from work on quantum computer systems, to extra correct quantum sensors, to work laying the foundations of a future quantum web – are collectively funded by £4.5 million from the UK’s Engineering and Physical Sciences Research Council (EPSRC) and simply over £5.2 million from the Japan Science and Technology Agency (JST). 

The Prime Minister additionally introduced a £6 million UK–Japan analysis programme on superior connectivity applied sciences, collectively funded by each governments.  

These applied sciences will assist to present seamless protection so that everybody can entry digital companies wherever they are, and guarantee networks can reliably stand up to cyberthreats and pure disasters. 

The programme is backed by £3 million from the Department for Science, Innovation and Technology, matched by £3 million from the Japanese Government. It will deal with synthetic intelligence in telecoms, non‑terrestrial networks like satellite tv for pc web, and ‘optical’ networks that promise to ship ultra-high capability and power effectivity. 

Together, these bulletins exhibit the energy of the UK–Japan science and technology partnership and a shared dedication to innovation that drives financial progress, improves lives and strengthens resilience in an more and more linked world. 

Notes to editors

Orchard Therapeutics Investment

The funding into Orchard Therapeutics is the most recent optimistic step for the UK’s essential Cell and Gene sector, which is at present house to over 90 superior remedy firms. The UK authorities stays dedicated to maintaining the UK on the forefront of cell and gene developments, constructing on its current standing as a trailblazer in CAR-T cell therapy- primarily used to deal with blood cancers – being the primary in Europe to make it commercially out there. 

Bobby Gaspar, M.D., Ph.D., co-founder and chief govt officer (CEO) of  Orchard Therapeutics mentioned: 

Since becoming a member of Kyowa Kirin, we now have remained dedicated to accelerating the belief of our shared imaginative and prescient of ending the devastation brought on by extreme genetic illnesses and delivering life-changing worth in medical care.

We stay as true to our mission as ever, and bolstering our presence, infrastructure, and inside capabilities in our Hammersmith lab and workplace facility is a essential part to making sure we stay properly positioned to proceed creating modern cell and gene therapies for the advantages of sufferers, physicians, well being care programs and society.

Kyowa Kirin President and Chief Operating Officer (COO) Abdul Mullick, Ph.D., mentioned: 

Orchard Therapeutics has change into a core pillar of our mission.

By including a gene and cell remedy modality with the potential to ship one‑time therapies, we’re investing totally aligned with our imaginative and prescient to create and ship life‑altering worth for sufferers. We additionally stay strongly dedicated to advancing innovation and growth within the UK along with the federal government’s assist.

Oxford Nanopore-Genesis Healthcare partnership

The uncommon illness screening pilot will see Oxford Nanopore introduce its new superior era nanopore-based sensing technology to assist consolidate quite a few current take a look at approaches right into a single, targeted genome take a look at, initially utilized to neuromuscular issues. 

Delivered by Genesis Healthcare, the take a look at will permit screening for greater than 70 at present under-diagnosed neuromuscular circumstances. Set to start within the second half 2026, the Oxford Nanopore-Genesis Healthcare partnership will straight assist targets to translate genomic analysis into scientific settings specified by the latest UK–Japan Health Memorandum of Cooperation.   

This is anticipated to generate sustained, recurring demand for UK-manufactured sequencing platforms and consumables, supporting high-skilled jobs, strengthen life sciences provide chains in each international locations and drive innovation in therapies, applied sciences, and fashions of take care of these uncommon neuromuscular circumstances.